Skip to main content
. 2014 Jan 6;2:2. doi: 10.1186/2213-0802-2-2

Table 3.

Trials of 2 nd generation TKI in acquired resistance setting

N OR% mPFS (mo) mOS (mo)
Afatinib
LUX LUNG I trial 40
Afatinib 390 7 3.3 10.8
Placebo 195 <1 1.1 12.0
LUX LUNG IV trial 42 61 8.2 4.4 19
XL647
Phase II trial52 41 3 3.6 16.1

<, less than.